Immuno-oncology company, Agenus asserted the launch of its proprietary anti- CTLA4 (AGEN1884) and anti-PD1 (AGEN2034) antibodies. The open-label Phase 1/2 study is designed to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of combination AGEN1884 and AGEN2034 in patients with advanced solid tumors.
Garo Armen, Ph.D., Chairman and CEO of Agenus said “Speedy advancement of combination trials with our proprietary CTLA-4 and PD-1 antibodies is key to our strategy of commercializing our I-O agents. In addition, we believe both agents are crucial for combinations with our portfolio of proprietary immune oncology therapeutics, Our antibodies were discovered, optimized, manufactured and advanced into the clinic at record speed because of our fully integrated capabilities.”